Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Incyte corporation save search
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
Published: 2023-02-10 (Crawled : 19:00) - biospace.com/
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: -0.3%
H: 0.1%
C: -2.15%
incb5470 results study phase 2
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
Published: 2022-09-05 (Crawled : 01:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
| Email alert
Add to watchlist
INCY | $51.28 -0.89% 87K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
| Email alert
Add to watchlist
obesity chinese trial phase 2
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
Published: 2022-08-10 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: -6.43%
H: 0.0%
C: -6.31%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.49%
H: 0.86%
C: 0.04%
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 1.13%
H: 0.52%
C: -0.58%
ibi112 chinese psoriasis study plague phase 2
Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint
Published: 2022-07-19 (Crawled : 01:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
ibi362 chinese control diabetes study phase 2
Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis
Published: 2022-07-04 (Crawled : 01:00) - prnewswire.com
INCY | $51.28 -0.89% 87K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $724.615 -1.04% 480K
|
Health Technology
| Email alert
Add to watchlist
ibi112 active study phase 2 ulcerative colitis
Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints
Published: 2022-06-08 (Crawled : 01:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 3.02%
H: 0.98%
C: 0.34%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 1.5%
H: 1.13%
C: -0.01%
ibi362 obesity chinese phase 2
Innovent and AnHeart Jointly Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1-TKI) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
phase 2
AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022
Published: 2022-06-06 (Crawled : 16:00) - biospace.com/
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
therapeutics asco phase 2
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
Published: 2022-03-01 (Crawled : 13:30) - biospace.com/
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
phase 2 trial therapeutics therapy cancer pancreatic enroll
Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3Kδ inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma
Published: 2021-12-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.82%
H: 0.92%
C: 0.66%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 3.76%
H: 3.79%
C: 1.89%
phase 2 phase 2 results results
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 00:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: 0.51%
phase 2 heart positive trial
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
Published: 2021-09-24 (Crawled : 00:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
phase 2 antibody trial psoriasis plague
Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
Published: 2021-09-17 (Crawled : 01:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
chinese phase 2 phase 2 results results
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
Published: 2021-09-16 (Crawled : 07:00) - globenewswire.com
MGNX | $14.96 -4.71% 51K
|
Health Technology
|
| O: -2.29%
H: 0.0%
C: -21.97%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: -0.69%
H: 2.94%
C: 2.89%
phase 2 phase 2/3 results
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-26 (Crawled : 00:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 1.53%
H: 1.12%
C: 0.26%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: -0.49%
H: 0.51%
C: -1.85%
phase 1 antibody phase 2
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-16 (Crawled : 01:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
phase 1 antibody phase 2
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 0.18%
H: 2.77%
C: 1.95%
chinese solid tumors phase 1 results phase 3 phase 2
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
XNCR | $18.91 -0.58% 62K
|
Health Technology
|
| O: 0.38%
H: 1.25%
C: -0.76%
MOR | News | $18.05 30K
|
Health Technology
|
| O: 3.74%
H: 3.11%
C: 2.76%
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 0.33%
H: 1.54%
C: 0.19%
treatment phase 2 results als
Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
INCY | $51.28 -0.89% 87K
|
Health Technology
|
| O: 0.5%
H: 1.3%
C: 1.16%
phase 2
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
SGBX | $0.26 80.43% 54M
|
Producer Manufacturing
LICN | $1.0 78.57% 3.3M
|
CSSE 4 | $0.2656 74.39% 9.7M
|
Consumer Services
BRFH 4 | $1.89 71.82% 32M
|
Manufacturing
BOF | $1.95 66.67% 920K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.13 56.5% 500K
|
Technology Services
PCSA | $2.28 40.74% 37M
|
Producer Manufacturing
EVA | $0.626 39.14% 2.3M
|
Process Industries
OPTN | $1.215 31.31% 12M
|
Health Services
Your saved searches
Save your searches and get alerts when important news are released.